For the first time, people suffering from diabetes will see technology to regulate medical devices through mobile smartphone apps, including remote insulin dosing.
According to Healthline, such functionality has been implied for a long time now. However, it hasn't been approved by the food and Drug Administration for use in diabetes devices. But that is about to change.
As the field of medicine looks to what lies ahead in new technology for diabetes this year, many may encounter some sort of "déjà vu."
After all, much of what had been anticipated last year was postponed because of the continuing worldwide pandemic.
Read Also: Treat Type 2 Diabetes by Adding This Tasty Food to Your Diet
A mobile device for measuring blood sugar
Technology for Insulin Delivery
Meaning, many of the forecasts of the year ahead are similar to what, at first, had been on tap one year earlier. Still, it is thrilling to look at new inventions projected to change the face of the daily management of the condition, from new insulin pumps and pens to CGMs or continuous glucose monitors and smart closed-loop technology, also called Artificial Pancreas or Automated Insulin Delivery (AID) systems.
The DiabetesMine team has been addressing industry earning calls, not to mention, talking with company insiders, as well as other experts to compile the summary of what is anticipated to happen in 2022, with some of the understandings and observations scattered in.
Remarkably, Tandem Diabetes Care is likely to be the first to reach the finish line in getting clearance from the FDA on a smartphone app that can be utilized to regulate a device for insulin delivery.
What is 'Remote Bolusing'?
With that additional function, the newly developed connect app launched in mid-2020 alongside the Control-IQ Control system of Tandem, will enable "remote bolusing," also known as insulin dosing through a mobile app for the currently accessible t: slim X2 insulin pump platform and beyond.
The tech firm had filed with the FDA its expanded mobile app functionality in late 2020, although the pandemic postponements meant that approval was not seen to come in 2021 as many had anticipated.
In the most recent public updates in early December, the leadership of Tandem noted that the firm switched its pipeline plans to accommodate an expected approval and launch this year.
This paved the way for the future insulin pump technology of Tandem, promising the first new form factor since the first launch of its original t: slim model in 2012.
Importance of Pre-Bolusing for a Person on Insulin
As specified in a Children's Health report, even the most modern "ultra-rapid acting," takes time for insulin to be absorbed and become available in the blood to decrease glucose levels.
According to the Endocrinology team at Children's Health, it doesn't take the challenge lightly. Specifically, certified diabetes educator Kim Jernigan said, managing glucose levels during meal times can be a struggle for all people suffering from type 1 diabetes, although especially for parents with young children who frequently have volatile eating behaviors. Nonetheless, there is no denying the evidence that pre-bolusing is helpful.
Information about this new diabetes technology is shown on Tandem Diabetes's YouTube video below:
RELATED ARTICLE: November is Diabetes Awareness Month!
Check out more news and information on Diabetes in Science Times.
